

Total Antioxidant Capacity, Salivary Catalase, and Superoxide Dismutase in Hashimoto's Thyroiditis Patients

Shahin Nosratzahi¹, Mahin Nosratzahi¹, Ebrahim Alijani², Abolfazl Payandeh³, Tahereh Nosratzahi⁴, Abdulmannan Charvaei⁵

¹ Department of Internal Medicine, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

² Department of Immunology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

³ Infectious Diseases and Tropical Medicine Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, Iran

⁴ Department of Oral and Maxillofacial Medicine, School of Dentistry, Zahedan University of Medical Sciences, Zahedan, Iran

⁵ School of Dentistry, Zahedan University of Medical Sciences, Zahedan, Iran

Received: 11 Feb. 2023; Accepted: 18 Oct. 2023

Abstract- Hashimoto's thyroiditis (HT) is one of the common causes of hypothyroidism. Although various factors are involved in its development, recently the role of oxidative stress in its pathogenesis has been known. The present study aimed to investigate the level of total antioxidant capacity (TAC), catalase (CAT), and salivary superoxide dismutase (SOD) in patients with HT compared with the control group. The present case-control design included patients aged 18-80 years suffering from HT referred to the endocrine clinic. Eligible patients were selected by the available sampling method. Complete unstimulated saliva was collected under a rest state in a comfortable room between 10:00 AM and 12:00 AM and a checklist was used to collect data. The chi-square, t-test, and Mann-Whitney U tests were used for data analysis using SPSS 22 software. The mean age of the participants was 36.55 ± 9.37 years (range: 20-56). The two groups were the same in terms of age and gender ($P > 0.05$). The findings indicated that the difference in the means CAT between the two groups was 22.63 which was strongly and statistically significant ($P < 0.001$). In this study, the level of TAC and SOD in Hashimoto's thyroid patients was decreased and the level of CAT was increased. These initial findings show that oxidative stress can be associated with Hashimoto's thyroid disease or the possibility of developing this disease increase.

© 2023 Tehran University of Medical Sciences. All rights reserved.

Acta Med Iran 2023;61(12):722-727.

Keywords: Hashimoto's thyroiditis; Antioxidant; Superoxide dismutase; Oxidative stress; Saliva

Introduction

Hashimoto's thyroiditis (HT) is a multifactorial disease and one of the most prevalent thyroid autoimmune disorders (1). HT, also called "chronic lymphocytic thyroiditis" or "autoimmune thyroiditis" was first described by Hakura Hashimoto in 1912 (2). In HT patients, the thyroid gland is hardened and enlarged with a characteristic pathological appearance (3). The presence of thyroid peroxidase autoantibodies (anti-TPO) is an important biomarker for the diagnosis of HT (4). The prevalence of HT in the general population is

10%, and women are 5-10 times more susceptible than men (5). The occurrence of HT is related to age, ethnicity, environmental factors, and gender. Excessive dietary iodine intake has been significantly suggested as an environmental trigger of HT. High consumption of iodine has a series of inhibitory effects on secretion and the biosynthesis of thyroid hormone. It has also shown that excessive consumption of iodine reduces cellular antioxidant activity in experimental animal models (6). Furthermore, recent prospective researches have revealed that even a minimal increase in iodine levels in iodine-replete areas is correlated with an increased

Corresponding Author: T. Nosratzahi

Department of Oral and Maxillofacial Medicine, School of Dentistry, Zahedan University of Medical Sciences, Zahedan, Iran
Tel: +98 9152345423, E-mail address: taherehnosratzahi@yahoo.com

Copyright © 2023 Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (<https://creativecommons.org/licenses/by-nc/4.0/>). Non-commercial uses of the work are permitted, provided the original work is properly cited

incidence of HT (7). The pathogenesis of HT is marked by the progressive destruction of thyroid cells and mechanisms including cell apoptosis and oxidative stress (8,9).

The participation of the oxidative stress mechanism in the pathogenesis of HT is still unclear (10). The characteristic of HT is the presence of blocking autoantibodies (TSH-R), which reduces the secretion of triiodothyronine (T3) and thyroxine (T4) (11). In HT, B and T lymphocytes, which are stimulated against thyroid peroxidase (TPO) and thyroglobulin, lead to inflammation and destruction of the thyroid. B and T lymphocytes may result in the overproduction of reactive oxygen species (ROS) through the enzyme NADPH (nicotinamide adenine dinucleotide phosphate) oxidase (12).

In thyroiditis, free radicals and ROS constantly generate and participate in pathological and physiological conditions (13). For example, hydrogen peroxide (H₂O₂) is essential for making thyroid hormones (14). However, some laboratory experimental studies showed that H₂O₂ also affects the process of cell death (15,16). Cells develop an extensive set of antioxidant activities to neutralize the effect of ROS. The antioxidants catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPX) have been identified in the thyroid gland (13). SOD catalyzes the conversion of two superoxide molecules into H₂O₂ and oxygen (17). CAT and GPX mainly remove H₂O₂ as the primary factor in the main antioxidant process (18).

In physiological conditions, ROS molecules that are crucial for thyroid hormone biosynthesis (during iodine oxidation and binding to amino acids) in epithelial cells of thyroid gland. However, H₂O₂ levels may increase excessively in the presence of certain stimuli including inflammation (activation of B and T lymphocytes), radiation, medications, chemicals, and excessive iodine intake (19-21). In this excessively increased H₂O₂ environment, thyrocytes undergo apoptosis, necrosis, and destruction as a result (22). Another condition that can lead to an increase in ROS in HT is the decrease in the synthesis of antioxidant enzymes due to the decline in thyroid hormone levels (10,13). In addition, it is also known that hyperlipidemia, which is caused by a low level of thyroid hormone, also leads to a rise in ROS (23).

Many oxidizing factors that have the ability to generate excessive production of ROS can lead to a change in the redox balance of the oral cavity (24). Previous studies showed that saliva and plasma antioxidants play an important role in the form of the

antioxidant barrier both in the mouth and in the whole body (25). Salivary peroxidase and CAT together neutralize the H₂O₂ formed in the mutagenesis reactions by SOD catalytic activity (26). The failure of the antioxidant activities may lead to oral cavity diseases including precancerous lesions, periodontitis and cancer. Evidence have revealed the change in salivary antioxidant barrier and the effect of oxidative stress result in the salivary gland dysfunction in the course of autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis, diabetes mellitus, Sjogren's syndrome, psoriasis vulgaris and multiple sclerosis (26-30). In general, a change in the total antioxidant capacity (TAC) in the saliva and an increase in the oxidative damage of salivary glands detected in the saliva of patients with autoimmune disorders (31).

Few studies assessed salivary redox homeostasis in HT, it seems necessary to evaluate the antioxidant capacity of saliva and the role of oxidative stress in causing salivary gland problems during HT. It should be mentioned that abnormality in the composition and amount of saliva secreted has a negative effect on the health of the mouth and the whole body (31). Therefore, understanding the mechanisms that lead to salivary gland dysfunction, evaluating the antioxidant salivary activities, and the role of oxidative stress in causing salivary gland dysfunction during HT seems essential. The present study aimed to investigate the level of TAC, CAT, and salivary SOD in patients with HT compared with the control group.

Materials and Methods

The present case-control design included patients aged 18-80 years suffering from HT referred to the endocrine clinic of a university-affiliated hospital in Zahedan, southeastern Iran. The sample size was calculated based on the formula of statistical test for assessing means equality between two parallel groups (32). According to the study by Lasoued *et al.*, (33), considering the significance level of 0.05, power of 0.95, means difference (ϵ) of 0.41, and nonresponse probability of 0.10, 30 patients with HT and 30 healthy individuals as a control group were computed and included in the study. Eligible patients were selected by the available sampling method.

The HT was defined as follows; decreased total Thyroxine (T4) <4.5 μ g/dL (normal range, 4.5-12 μ g/dL), in association with elevated thyroid stimulating hormone (TSH) \geq 10 mIU/L, and positive anti-TPO Ab >16 IU/ml (normal range up to 16 IU/ml) or

Salivary antioxidant activity in HT

antithyroglobulin >100 mIU/L (normal range up to 100 mIU/L). If the initial tests were positive for hypothyroidism, to rule out transient hypothyroidism, the tests were repeated three months later, and if the hypothyroidism was approved, the subjects were included in the study.

Controls referred to the Department of Oral Diseases School of Dentistry were frequently matched with the case groups in terms of age and gender. Inclusion criteria were; 1. Not having gingivitis, periodontitis, or an active focus of odontogenic infections for subsequent examinations. 2. Not taking any medication that can affect the secretion of saliva (antidepressants or antihypertensive drugs) or its redox processes (antioxidant supplements, vitamins). Subjects with any autoimmune diseases (rheumatoid arthritis, type 1 diabetes, psoriasis, scleroderma, Sjogren's syndrome, lupus, etc.), subjects with depression, and subjects with smoking, alcohol consumption, stimulants, and incomplete checklists were excluded.

A written informed consent was signed by the participants. Complete unstimulated saliva was collected under a rest state in a comfortable room between 10:00 AM and 12:00 AM. Subjects must be at least 120 minutes before taking samples to avoid eating, drinking, smoking, and using mouthwash. 5 ml of non-irritating saliva sample was collected by pouring saliva out of the mouth in the absence of chewing movements. One of the best methods for collecting whole saliva is the spitting method. After confirmation, the saliva samples were centrifuged (2500 g, 10 minutes), and the supernatant

was immediately separated from the saliva and stored at -70° C for further evaluation (34). Laboratory measurements of saliva concentration, total antioxidant, CAT, and salivary SOD levels were determined by Enzyme-linked immunosorbent assay (ELISA) using Navand biological kits (Nactaz™ CAT Activity Assay Kit, Nazdox™ SOD Activity Assay Kit) with 95% sensitivity.

The data were analyzed using SPSS version 22. Descriptive statistics (e.g., frequency, percentage and mean ± standard deviation (SD) were calculated. Given the normal distribution of the studied variables including the TAC and the salivary SOD, the parametric t-test was employed. The chi-square test was used to compare the frequency of sex in patients with HT and healthy controls. Also, due to the non-normal distribution of CAT activity, a non-parametric Mann-Whitney U test was used. The significance level was set at 0.05.

Results

The mean age of the participants was 36.55±9.37 years (range: 20-56). Table 1 shows that the two groups were the same in terms of age and gender ($P>0.05$). The Comparison of the TAC, CAT, and salivary SOD in patients with HT and healthy control group were summarized in Table 2. The findings indicated that the difference in the means CAT between the two groups was 22.63 which was strongly and statistically significant ($P<0.001$).

Table 1. The comparison of the mean age and gender of subjects in HT and healthy control groups

Variables	Patients with HT N=30	Healthy controls N=30	P
Age (yr)	35.04±9.62 ^a	37.89±9.11	0.283
Gender	Female	21 (70)	0.514
	Male	9 (30)	

^a Data were summarized as mean±SD or frequency (percent)
Abbreviations: HT, Hashimoto's thyroiditis

Table 2. The Comparison of the TAC, CAT, and SOD in patients with HT with the control group

Variables mean±SD	Patients with N=30	Healthy controls N=30	CI (95%)		P
			Lower	Upper	
TAC	257.67±90.06	268.35±55.25	-53.70	32.34	0.62
CAT	33.06±11.43	10.43±4.6	18.32	26.94	<0.001*
SOD	47.50±26.78	60.04±24.29	-26.90	1.83	0.09

*Significant

Abbreviations: HT, Hashimoto's thyroiditis; TAC, total antioxidant capacity; CAT, catalase; SOD, salivary superoxide dismutase

Discussion

The present study aimed to investigate the level of

TAC, CAT, and salivary SOD in patients with HT compared with controls. Our results showed that the mean salivary CAT in the patients was significantly

higher than in the healthy controls. The present findings also revealed that the mean of TAC and SOD in patients with HT was lower than in the healthy control group, but these differences were not significant.

The present study in agreement with previous studies concerning salivary redox homeostasis indicated that CAT activity was higher in patients with HT than in the healthy controls (35,36). Similarly, numerous studies have indicated that the TAC and SOD activity decreased in the patients with HT (36). For instance, the results of studies by Ates *et al.*, (37) showed that oxidative stress parameters increase continuously during all stages of HT. Also, Morawska and her colleagues (35) conducted a study to assess salivary redox homeostasis in patients with HT and showed a decline in antioxidant activity (82%) and enhanced generation of ROS as well as excessive oxidative agents in the plasma of patients with HT in euthyrosis. Moreover, medical literature about the TAC in hypothyroidism and hyperthyroidism agree with our findings (38-40).

The present study is one of the few studies that investigated CAT activity levels in HT. The result of a study conducted by Lassoued and his colleagues showed that CAT activities increased significantly only for papillary thyroid cancer (PTC) and HT patients, and the results of this study are in line with the present study (33). In a study done by Naazeri *et al.*, (41) on an Iranian sample with hypo- and hyperthyroidism, the enhanced activity of CAT and SOD are also reported, and the results of the study are in agreement with our findings. The results of several studies showed that CAT activity increased in patients with hyperthyroidism (42,43). However, Pasupathi and Sahoo colleagues showed that the CAT activity in patients with hypothyroidism was lower than in the controls, which is inconsistent with the present study (44,45). The precise cause for the decrease in CAT activity, an enzyme known for its antioxidant properties, in this particular ailment, remains elusive. More studies are needed in this field.

The results of the present study showed that the decreased level of salivary SOD in patients with HT in compared with controls. In the study of Pasupathi *et al.*, (44), SOD activity was lower in patients with hypothyroidism than in controls, which is in line with our study. The reduced levels of these antioxidants are due to increased oxidative stress in patients. In agreement with our findings, Resch *et al.*, showed decreased SOD activity in patients with hypothyroidism in comparison with the controls.

The present study had limitations, which can be

pointed to the small sample size in the studied groups and also that only two parameters of several parameters of oxidative stress were measured.

In this study, the level of total antioxidant and superoxide dismutase in patients with HT was decreased and the level of catalase was increased. These initial findings show that oxidative stress can be associated with HT disease or the possibility of developing this disease increase.

References

1. Shukla SK, Singh G, Ahmad S, Pant P. Infections, genetic and environmental factors in pathogenesis of autoimmune thyroid diseases. *Microb Pathog* 2018;116:279-88.
2. San Yap P, Ali O, Truran P, Aspinall S. Thyrotoxicosis and thyroiditis. *Surgery (Oxf)* 2020;38:794-800.
3. Caturegli P, De Remigis A, Rose N. Hashimoto thyroiditis: clinical and diagnostic criteria. *Autoimmun Rev* 2014;13:391-7.
4. Espenbetova M, Kuzmina N, Zubkov A, Akhmetova V, Zamanbekova Z, Krykpaeva A, et al. Epitopes specificity of antibodies to thyroid peroxidase in patients with Graves' disease, Hashimoto's thyroiditis and overlap-syndrome. *J Clin Transl Endocrinol* 2022;27:100293.
5. Klubo-Gwiedzinska J, Wartofsky L. Hashimoto thyroiditis: An evidence-based guide: Etiology, diagnosis and treatment. *Pol Arch Intern Med* 2022;132:16222.
6. Phagoora J, Saini S, Raghunathan A, Reji J, Shabir A, Wanis M, et al. Hashimoto Thyroiditis-A Comprehensive Review. *Physician J Med* 2023;2.
7. Farebrother J, Zimmermann MB, Andersson M. Excess iodine intake: sources, assessment, and effects on thyroid function. *Ann N Y Acad Sci* 2019;1446:44-65.
8. da Silva GB, Yamauchi MA, Bagatini MD. Oxidative stress in Hashimoto's thyroiditis: possible adjuvant therapies to attenuate deleterious effects. *Mol Cell Biochem* 2023;478:949-66.
9. Popławska-Kita A. Markers of Both Autoimmune and Apoptotic Processes in Initiation and Progression of Hashimoto's Thyroiditis. *J Clin Med Images* 2020;4:1-6.
10. Ates I, Arikan MF, Altay M, Yilmaz FM, Yilmaz N, Berker D, et al. The effect of oxidative stress on the progression of Hashimoto's thyroiditis. *Arch Physiol Biochem* 2018;124:351-6.
11. Ragusa F, Fallahi P, Elia G, Gonnella D, Paparo SR, Giusti C, et al. Hashimoto's thyroiditis: Epidemiology, pathogenesis, clinic and therapy. *Best Pract Res Clin Endocrinol Metab* 2019;33:101367.
12. Ryzewska M, Jaromin M, Pasierowska IE, Stożek K, Bossowski A. Role of the T and B lymphocytes in

- pathogenesis of autoimmune thyroid diseases. *Thyroid Res* 2018;11:2.
13. Kochman J, Jakubczyk K, Bargiel P, Janda-Milczarek K. The influence of oxidative stress on thyroid diseases. *Antioxidants* 2021;10:1442.
 14. Carvalho DP, Dupuy C. Thyroid hormone biosynthesis and release. *Mol Cell Endocrinol* 2017;458:6-15.
 15. Hack CT, Buck T, Bagnjuk K, Eubler K, Kunz L, Mayr D, et al. A Role for H₂O₂ and TRPM2 in the Induction of Cell Death: Studies in KGN Cells. *Antioxidants (Basel)* 2019;8:518.
 16. Rafeaie R, Khastar H, Garmabi B, Taleb M, Norouzi P, Khaksari M. Hydrogen sulfide protects hippocampal CA1 neurons against lead mediated neuronal damage via reduction oxidative stress in male rats. *J Chem Neuroanat* 2021;112:101917.
 17. Winterbourn CC. Biological chemistry of superoxide radicals. *ChemTexts* 2020;6:7.
 18. Ighodaro O, Akinloye O. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. *Alexandria J Med* 2018;54:287-93.
 19. Ilnatowicz P, Drywień M, Wątor P, Wojsiat J. The importance of nutritional factors and dietary management of Hashimoto's thyroiditis. *Ann Agric Environ Med* 2020;27:184-93.
 20. Cenesiz S. The role of oxidant and antioxidant parameters in the infectious diseases: A systematic literature review. *Kafkas Univ Vet Fak Derg* 2020;26:849-58.
 21. Rai G, Kumar A, Mahobiya P. The effect of radiation on thyroid gland. *Int J Biol Res* 2018;3:217-22.
 22. Morshed SA, Davies TF. Understanding thyroid cell stress. *J Clin Endocrinol Metab.* 2020;105:e66-9.
 23. Duntas LH, Brenta G. A renewed focus on the association between thyroid hormones and lipid metabolism. *Front Endocrinol (Lausanne)* 2018;9:511.
 24. Żukowski P, Maciejczyk M, Waszkiel D. Sources of free radicals and oxidative stress in the oral cavity. *Arch Oral Biol* 2018;92:8-17.
 25. Jurczak A, Kościelniak D, Skalniak A, Papież M, Vyhouskaya P, Krzyściak W. The role of the saliva antioxidant barrier to reactive oxygen species with regard to caries development. *Redox Rep* 2017;22:524-33.
 26. Čižárová B, Tomečková V, Hubková B, Hurajtová A, Ohlasová J, Birková A. Salivary redox homeostasis in human health and disease. *Int J Mol Sci* 2022;23:10076.
 27. Kumar J, Teoh SL, Das S, Mahakknakrauh P. Oxidative stress in oral diseases: understanding its relation with other systemic diseases. *Front Physiol* 2017;8:693.
 28. Skutnik-Radziszewska A, Maciejczyk M, Fejfer K, Krahel J, Flisiak I, Kołodziej U, et al. Salivary Antioxidants and Oxidative Stress in Psoriatic Patients: Can Salivary Total Oxidant Status and Oxidative Status Index Be a Plaque Psoriasis Biomarker? *Oxid Med Cell Longev* 2020;2020:9086024.
 29. Żukowski P, Maciejczyk M, Matczuk J, Kurek K, Waszkiel D, Żendzian-Piotrowska M, et al. Effect of N-acetylcysteine on antioxidant defense, oxidative modification, and salivary gland function in a rat model of insulin resistance. *Oxid Med Cell Longev* 2018;2018:6581970.
 30. Maciejczyk M, Zalewska A, Ładny JR. Salivary antioxidant barrier, redox status, and oxidative damage to proteins and lipids in healthy children, adults, and the elderly. *Oxid Med Cell Longev.* 2019;2019:4393460 .
 31. Dąbrowska ZN, Bijowski K, Dąbrowska E, Pietruska M. Effect of oxidants and antioxidants on oral health. *Med Ogólna Nauki Zdr* 2020;26:87-93.
 32. Chow SC, Shao J, Wang H, Lohnygina Y. Sample size calculations in clinical research. *Chapman and Hall/CRC*; 2017.
 33. Lassoued S, Mseddi M, Mnif F, Abid M, Guermazi F, Masmoudi H, et al. A comparative study of the oxidative profile in Graves' disease, Hashimoto's thyroiditis, and papillary thyroid cancer. *Biol Trace Elem Res* 2010;138:107-15.
 34. Bhattarai KR, Kim HR, Chae HJ. Compliance with Saliva Collection Protocol in Healthy Volunteers: Strategies for Managing Risk and Errors. *Int J Med Sci* 2018;15:823-31.
 35. Morawska K, Maciejczyk M, Popławski Ł, Popławska-Kita A, Kretowski A, Zalewska A. Enhanced Salivary and General Oxidative Stress in Hashimoto's Thyroiditis Women in Euthyrosis. *J Clin Med* 2020;9:2102.
 36. Ortarzewska M, Nijakowski K, Kolasińska J, Gruszczyński D, Ruchała MA, Lehmann A, et al. Salivary Alterations in Autoimmune Thyroid Diseases: A Systematic Review. *Int J Environ Res Public Health* 2023;20:4849.
 37. Ates I, Yilmaz FM, Altay M, Yilmaz N, Berker D, Güler S. The relationship between oxidative stress and autoimmunity in Hashimoto's thyroiditis. *Eur J Endocrinol* 2015;173:791-9.
 38. Olia BH, Khadem Ansari MH, Rasmi Y, Hasanzadeh-Moghadam M. Evaluation of malondialdehyde levels and total antioxidant capacity in patients with hyperthyroidism. *Int J Res App Basic Med Sci* 2019;5:121-7.
 39. Najafi Z, Zarban A, Chamani E, Honarbakhsh M, Sharifzadeh G. Comparison of biochemical and oxidative stress parameters in hypo and hyperthyroid rat models. *Mod Care J.* 2020;17:e102444.

40. YAZICI C, Keçeci T, Hatipoğlu D. The effect of coenzyme Q10 on blood plasma nitric oxide and total antioxidant capacity levels in hypothyroidism-induced rats. *J Istanbul Vet Sci* 2021;5:19-26.
41. Naazeri S, Rostamian M, Hedayati M. Impact of thyroid dysfunction on antioxidant capacity, superoxide dismutase and catalase activity. *Zahedan J Res Med Sci* 2014;16:51-4.
42. Komosinska-Vassev K, Olczyk K, Kucharz EJ, Marcisz C, Winsz-Szczotka K, Kotulska A. Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves' disease during therapy. *Clin Chim Acta* 2000;300:107-17.
43. Bednarek J, Wysocki H, Sowinski J. Oxidation products and antioxidant markers in plasma of patients with Graves' disease and toxic multinodular goiter: effect of methimazole treatment. *Free Radic Res* 2004;38:659-64.
44. Pasupathi P, Latha R. Free radical activity and antioxidant defense mechanisms in patients with hypothyroidism. *Thyroid Sci* 2008;3:1-6.
45. Sahoo DK, Roy A, Bhanja S, Chainy GB. Hypothyroidism impairs antioxidant defence system and testicular physiology during development and maturation. *Gen Comp Endocrinol* 2008;156:63-70.